Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators..

N Engl J Med. 2008 Sep 25;359(13):1317-29. doi: 10.1056/NEJMoa0804656.

2.

Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.

Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, Barber PA, Bladin C, De Silva DA, Byrnes G, Chalk JB, Fink JN, Kimber TE, Schultz D, Hand PJ, Frayne J, Hankey G, Muir K, Gerraty R, Tress BM, Desmond PM; EPITHET investigators..

Lancet Neurol. 2008 Apr;7(4):299-309. doi: 10.1016/S1474-4422(08)70044-9. Epub 2008 Feb 28.

PMID:
18296121
3.

Comparison of CT perfusion and angiography and MRI in selecting stroke patients for acute treatment.

Wintermark M, Meuli R, Browaeys P, Reichhart M, Bogousslavsky J, Schnyder P, Michel P.

Neurology. 2007 Feb 27;68(9):694-7.

PMID:
17325279
4.

Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study.

Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, Bammer R, Kakuda W, Lansberg MG, Shuaib A, Coplin W, Hamilton S, Moseley M, Marks MP; DEFUSE Investigators..

Ann Neurol. 2006 Nov;60(5):508-17.

PMID:
17066483
5.

Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.

Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W; DEDAS Investigators..

Stroke. 2006 May;37(5):1227-31. Epub 2006 Mar 30.

6.

Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke.

Wintermark M, Flanders AE, Velthuis B, Meuli R, van Leeuwen M, Goldsher D, Pineda C, Serena J, van der Schaaf I, Waaijer A, Anderson J, Nesbit G, Gabriely I, Medina V, Quiles A, Pohlman S, Quist M, Schnyder P, Bogousslavsky J, Dillon WP, Pedraza S.

Stroke. 2006 Apr;37(4):979-85. Epub 2006 Mar 2.

7.

The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.

Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, Soehngen M, Warach S; DIAS Study Group..

Stroke. 2005 Jan;36(1):66-73. Epub 2004 Nov 29.

8.

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators.; ECASS Trials Investigators.; NINDS rt-PA Study Group Investigators..

Lancet. 2004 Mar 6;363(9411):768-74.

PMID:
15016487
9.

Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration.

Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL.

Stroke. 2003 Feb;34(2):537-43.

10.

Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients.

Wintermark M, Reichhart M, Cuisenaire O, Maeder P, Thiran JP, Schnyder P, Bogousslavsky J, Meuli R.

Stroke. 2002 Aug;33(8):2025-31.

11.

Plasminogen activation is stimulated by prion protein and regulated in a copper-dependent manner.

Ellis V, Daniels M, Misra R, Brown DR.

Biochemistry. 2002 Jun 4;41(22):6891-6.

PMID:
12033920
13.

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P.

Lancet. 1998 Oct 17;352(9136):1245-51.

PMID:
9788453
14.

Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging.

Baird AE, Benfield A, Schlaug G, Siewert B, Lövblad KO, Edelman RR, Warach S.

Ann Neurol. 1997 May;41(5):581-9.

PMID:
9153519
15.

In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid beta-peptide analogues.

Kingston IB, Castro MJ, Anderson S.

Nat Med. 1995 Feb;1(2):138-42.

PMID:
7585010
16.

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH, et al.

JAMA. 1995 Oct 4;274(13):1017-25.

PMID:
7563451
17.

Tissue plasminogen activator for acute ischemic stroke.

National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group..

N Engl J Med. 1995 Dec 14;333(24):1581-7.

18.

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

TIMI Study Group..

N Engl J Med. 1985 Apr 4;312(14):932-6. No abstract available.

PMID:
4038784

Supplemental Content

Support Center